According to VIC Research, the Leukemia Molecular Diagnostics market is projected to reach USD 3,397.23 million in 2026 and grow to USD 6,853.82 million by 2033, registering a CAGR of 10.55% during the forecast period (2026–2033). The China market has also experienced rapid growth in recent years and is expected to reach USD Million by 2026, accounting for approximately % of the global market share.
This report provides a comprehensive overview of the global Leukemia Molecular Diagnostics industry, with a particular focus on key countries and the Chinese market. It covers historical data from 2021 to 2025, uses 2026 as the base year, and presents forecasts through 2033. The study analyzes the sales performance, market share, pricing, sales volume, revenue, and gross profit of leading companies across major regions, while also examining their strategic developments. In addition, it offers detailed market segmentation by manufacturer, product type, application, and region, providing valuable insights into market trends and growth opportunities.
Geographically, the report covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, providing an in-depth assessment of current market conditions and future growth prospects. By incorporating industry policies and the latest technological developments, it highlights the unique characteristics of each regional market, enabling businesses to better understand competitive dynamics and optimize their global expansion strategies.
The data presented in this report is compiled from a wide range of authoritative sources to ensure a reliable analytical foundation. Macroeconomic data is obtained from national statistical agencies and international economic institutions, while industry-specific information is sourced from relevant trade associations. Corporate data is collected through public disclosures, interviews, and reputable third-party databases, with pricing information derived from comprehensive market monitoring systems. Through rigorous data integration and cross-validation, the report ensures accuracy, objectivity, and forward-looking insights.
The report focuses on the following companies:
Ruiang Gene
Zhishan Bio
Zhijiang Bio
Jinpujia Medical
Merle Bio
Herui Gene
Aicon Bio
Annuouda
Beijing Wantai
Haixi Bio
Qiagen
Abbott
Kanglu Biotechnology
Guangzhou Anbiping
Based on different product types, the following categories are included:
PCR
FISH
DNA Sequencing
Gene Chip
By different sectors and application scenarios, the report primarily covers the following aspects:
Clinical Diagnosis
Drug Screening
Research
Major consumption regions include the following:
US
Europe
China
Japan
Korea
India
Southeast Asia
South America
This report is organized into five main sections comprising 10 chapters. The contents of each section are summarized as follows:
Part One is the Foundational Section, primarily comprising Chapter 1, which introduces the market overview, basic concepts, product definition, key characteristics, product types, major application scenarios, and the industrial chain structure of Leukemia Molecular Diagnostics.
Part Two is the Global Section, primarily comprising Chapters 2–4. This section analyzes global sales volume, market size, and growth forecasts across different Leukemia Molecular Diagnostics market segments and application areas.
Part Three is the Regional Section, primarily comprising Chapters 5–6. It focuses on sales volume, market size, and growth forecasts across the major regional markets for Leukemia Molecular Diagnostics.
Part Four is the Corporate Analysis, primarily covering Chapters 7–8. This section profiles the leading global Leukemia Molecular Diagnostics companies, including their product portfolios, technologies, applications, sales performance, market share, and industry concentration.
Part Five: Outlook, comprising Chapters 9–10. This section evaluates the development environment, market opportunities, and potential risks within the Leukemia Molecular Diagnostics industry, while providing an outlook for future market growth.
-
-
- Market Overview
1.1 Product Introduction, Application, Picture
1.2 Global Leukemia Molecular Diagnostics Market by Value
1.2.1 Global Leukemia Molecular Diagnostics Revenue by Type
1.2.2 Global Leukemia Molecular Diagnostics Market Share by Value (%)
1.3 Global Leukemia Molecular Diagnostics Market by Production
1.3.1 Global Leukemia Molecular Diagnostics Production by Type
1.3.2 Global Leukemia Molecular Diagnostics Market Share by Production (%) - Key Growth Drivers of the Leukemia Molecular Diagnostics Industry
2.1 Historical and Forecast Global Leukemia Molecular Diagnostics Demand
2.2 Largest Application Segment for Leukemia Molecular Diagnostics (2021–2032)
2.3 Major Downstream Companies in the China Market (2026) - Global and Regional Market Analysis
3.1 Regional Market Size by Production and Demand (2026)
3.2 Regional Market Share by Revenue (2026–2032)
3.3 Market Concentration Ratio (CR5 & CR10) of the Leukemia Molecular Diagnostics Market
3.4 Mergers & Acquisitions and Expansion Plans - US Leukemia Molecular Diagnostics Production and Demand (2021–2032)
4.1 Current and Forecast Production Breakdown by Type
4.2 Current and Forecast Demand Breakdown by Type
4.3 Current and Forecast Demand Breakdown by Application
4.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
4.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - Europe Leukemia Molecular Diagnostics Production and Demand (2021–2032)
5.1 Current and Forecast Production Breakdown by Type
5.2 Current and Forecast Demand Breakdown by Type
5.3 Current and Forecast Demand Breakdown by Application
5.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
5.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - China Leukemia Molecular Diagnostics Production and Demand (2021–2032)
6.1 Current and Forecast Production Breakdown by Type
6.2 Current and Forecast Demand Breakdown by Type
6.3 Current and Forecast Demand Breakdown by Application
6.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
6.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - Japan Leukemia Molecular Diagnostics Production and Demand (2021–2032)
7.1 Current and Forecast Production Breakdown by Type
7.2 Current and Forecast Demand Breakdown by Type
7.3 Current and Forecast Demand Breakdown by Application
7.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
7.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - India Leukemia Molecular Diagnostics Production and Demand (2021–2032)
8.1 Current and Forecast Production Breakdown by Type
8.2 Current and Forecast Demand Breakdown by Type
8.3 Current and Forecast Demand Breakdown by Application
8.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
8.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - Korea Leukemia Molecular Diagnostics Production and Demand (2021–2032)
9.1 Current and Forecast Production Breakdown by Type
9.2 Current and Forecast Demand Breakdown by Type
9.3 Current and Forecast Demand Breakdown by Application
9.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
9.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - Southeast Asia Leukemia Molecular Diagnostics Production and Demand (2021–2032)
10.1 Current and Forecast Production Breakdown by Type
10.2 Current and Forecast Demand Breakdown by Type
10.3 Current and Forecast Demand Breakdown by Application
10.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
10.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - South America Leukemia Molecular Diagnostics Production and Demand (2021–2032)
11.1 Current and Forecast Production Breakdown by Type
11.2 Current and Forecast Demand Breakdown by Type
11.3 Current and Forecast Demand Breakdown by Application
11.4 Current and Forecast Revenue Breakdown by Type (2021–2032)
11.5 Current and Forecast Revenue Breakdown by Application (2021–2032) - Global Leukemia Molecular Diagnostics Average Price Trend
13.1 Market Price by Product Type in the US (2021–2026)
13.2 Market Price by Product Type in Europe (2021–2026)
13.3 Market Price by Product Type in China (2021–2026)
13.4 Market Price by Product Type in Japan (2021–2026)
13.5 Market Price by Product Type in India (2021–2026)
13.6 Market Price by Product Type in Korea (2021–2026)
13.7 Market Price by Product Type in Southeast Asia (2021–2026) - Industrial Chain Analysis
14.1 Leukemia Molecular Diagnostics Industry Chain Analysis
14.2 Downstream Analysis
14.3 Technology Trends in Leukemia Molecular Diagnostics - Competitive Landscape
15.1 Company One
15.1.1 Ruiang Gene Profile
15.1.2 Ruiang Gene Product Introduction
15.1.3 Ruiang Gene Leukemia Molecular Diagnostics Sales and Revenue
15.1.4 Strategic Initiatives15.2 Zhishan Bio
15.2.1 Zhishan Bio Profile
15.2.2 Zhishan Bio Product Introduction
15.2.3 Zhishan Bio Leukemia Molecular Diagnostics Sales and Revenue
15.2.4 Strategic Initiatives15.3 Zhijiang Bio
15.3.1 Zhijiang Bio Profile
15.3.2 Zhijiang Bio Product Introduction
15.3.3 Zhijiang Bio Leukemia Molecular Diagnostics Sales and Revenue
15.3.4 Strategic Initiatives15.4 Jinpujia Medical
15.4.1 Jinpujia Medical Profile
15.4.2 Jinpujia Medical Product Introduction
15.4.3 Jinpujia Medical Leukemia Molecular Diagnostics Sales and Revenue
15.4.4 Strategic Initiatives15.5 Merle Bio
15.5.1 Merle Bio Profile
15.5.2 Merle Bio Product Introduction
15.5.3 Merle Bio Leukemia Molecular Diagnostics Sales and Revenue
15.5.4 Strategic Initiatives15.6 Herui Gene
15.6.1 Herui Gene Profile
15.6.2 Herui Gene Product Introduction
15.6.3 Herui Gene Leukemia Molecular Diagnostics Sales and Revenue
15.6.4 Strategic Initiatives15.7 Aicon Bio
15.7.1 Aicon Bio Profile
15.7.2 Aicon Bio Product Introduction
15.7.3 Aicon Bio Leukemia Molecular Diagnostics Sales and Revenue
15.7.4 Strategic Initiatives15.8 Annuouda
15.8.1 Annuouda Profile
15.8.2 Annuouda Product Introduction
15.8.3 Annuouda Leukemia Molecular Diagnostics Sales and Revenue
15.8.4 Strategic Initiatives15.9 Beijing Wantai
15.10 Haixi Bio
15.11 Qiagen
15.12 Abbott
15.13 Kanglu Biotechnology
15.14 Guangzhou Anbiping
- Conclusion
- Research Method
- Market Overview
-
-
Figure 1. Total Demand by Application of Leukemia Molecular Diagnostics Industry (Volume)
Figure 2. Leukemia Molecular Diagnostics Production & Demand by Regions in 2026
Figure 3. Regional Market Share by Revenue (2026 & 2032)
Figure 4. Top 10 and Top 5 Players’ Market Share by Revenue in 2026
Figure 5. US Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Revenue Breakdown by Type (%)
Figure 22. Revenue Breakdown by Application (%)
Figure 23. Japan Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 24. Production Breakdown by Type (%)
Figure 25. Demand Breakdown by Type (%)
Figure 26. Demand Breakdown by Application (%)
Figure 27. Revenue Breakdown by Type (%)
Figure 28. Revenue Breakdown by Application (%)
Figure 29. India Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 30. Production Breakdown by Type (%)
Figure 31. Demand Breakdown by Type (%)
Figure 32. Demand Breakdown by Application (%)
Figure 33. Revenue Breakdown by Type (%)
Figure 34. Revenue Breakdown by Application (%)
Figure 35. Korea Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 36. Production Breakdown by Type (%)
Figure 37. Demand Breakdown by Type (%)
Figure 38. Demand Breakdown by Application (%)
Figure 39. Revenue Breakdown by Type (%)
Figure 40. Revenue Breakdown by Application (%)
Figure 41. Southeast Asia Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 42. Production Breakdown by Type (%)
Figure 43. Demand Breakdown by Type (%)
Figure 44. Demand Breakdown by Application (%)
Figure 45. Revenue Breakdown by Type (%)
Figure 46. Revenue Breakdown by Application (%)
Figure 47. South America Leukemia Molecular Diagnostics Production & Demand (2021–2032)
Figure 48. Production Breakdown by Type (%)
Figure 49. Demand Breakdown by Type (%)
Figure 50. Demand Breakdown by Application (%)
Figure 51. Revenue Breakdown by Type (%)
Figure 52. Revenue Breakdown by Application (%)
Figure 53. Industrial Chain AnalysisTable 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Applications, and Images
Table 3. Leukemia Molecular Diagnostics Revenue by Type (Million USD), 2021–2032
Table 4. Leukemia Molecular Diagnostics Production by Type, 2021–2032
Table 5. Leukemia Molecular Diagnostics Demand by Application, 2021–2032
Table 6. Leukemia Molecular Diagnostics Revenue by Application (Million USD), 2021–2032
Table 7. Major Downstream Companies in China
Table 8. Regional Market Share by Production and Demand (2026)
Table 9. Regional Market Share by Revenue (2026 & 2032)
Table 10. Ranking of Global Top Leukemia Molecular Diagnostics Companies by Revenue and Market Concentration Ratio (2026)
Table 11. Mergers, Acquisitions, and Expansion Plans
Table 12. US Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 13. Current and Forecast Production Breakdown by Type (2021–2032)
Table 14. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 15. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 16. Current and Forecast Revenue Breakdown by Type
Table 17. Current and Forecast Revenue Breakdown by Application
Table 18. Europe Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 19. Current and Forecast Production Breakdown by Type (2021–2032)
Table 20. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 21. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 22. Current and Forecast Revenue Breakdown by Type
Table 23. Current and Forecast Revenue Breakdown by Application
Table 24. China Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 25. Current and Forecast Production Breakdown by Type (2021–2032)
Table 26. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 27. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 28. Current and Forecast Revenue Breakdown by Type
Table 29. Current and Forecast Revenue Breakdown by Application
Table 30. Japan Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 31. Current and Forecast Production Breakdown by Type (2021–2032)
Table 32. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 33. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 34. Current and Forecast Revenue Breakdown by Type
Table 35. Current and Forecast Revenue Breakdown by Application
Table 36. India Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 37. Current and Forecast Production Breakdown by Type (2021–2032)
Table 38. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 39. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 40. Current and Forecast Revenue Breakdown by Type
Table 41. Current and Forecast Revenue Breakdown by Application
Table 42. Korea Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 43. Current and Forecast Production Breakdown by Type (2021–2032)
Table 44. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 45. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 46. Current and Forecast Revenue Breakdown by Type
Table 47. Current and Forecast Revenue Breakdown by Application
Table 48. Southeast Asia Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 49. Current and Forecast Production Breakdown by Type (2021–2032)
Table 50. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 51. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 52. Current and Forecast Revenue Breakdown by Type
Table 53. Current and Forecast Revenue Breakdown by Application
Table 54. South America Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 55. Current and Forecast Production Breakdown by Type (2021–2032)
Table 56. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 57. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 58. Current and Forecast Revenue Breakdown by Type
Table 59. Current and Forecast Revenue Breakdown by Application
Table 60. Market Price by Type in the US (2021–2026)
Table 61. Market Price by Type in Europe (2021–2026)
Table 62. Market Price by Type in China (2021–2026)
Table 63. Market Price by Type in Japan (2021–2026)
Table 64. Market Price by Type in India (2021–2026)
Table 65. Market Price by Type in Korea (2021–2026)
Table 66. Market Price by Type in Southeast Asia (2021–2026)
Table 67. Key Downstream Customers by Application
Table 68. Ruiang Gene Profile
Table 69. Ruiang Gene Product Introduction
Table 70. Ruiang Gene Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 71. Zhishan Bio Profile
Table 72. Zhishan Bio Product Introduction
Table 73. Zhishan Bio Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 74. Zhijiang Bio Profile
Table 75. Zhijiang Bio Product Introduction
Table 76. Zhijiang Bio Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 77. Jinpujia Medical Profile
Table 78. Jinpujia Medical Product Introduction
Table 79. Jinpujia Medical Leukemia Molecular Diagnostics Sales (Units), Revenue (Million USD), and Price (2021–2026)
Table 83. Herui Gene Profile
Table 84. Herui Gene Product Introduction
Table 85. Herui Gene Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 86. Aicon Bio Profile
Table 87. Aicon Bio Product Introduction
Table 88. Aicon Bio Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 89. Annuouda Profile
Table 90. Annuouda Product Introduction
Table 91. Annuouda Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
-
Research Methodology
VICResearch follows a structured research methodology to ensure the accuracy, reliability, and quality of every market report. All analysts undergo extensive training and apply a five-stage research process to validate data and deliver actionable market insights.
Stage 1: Secondary Research
The research process begins with extensive secondary research using industry magazines, trade associations, government publications, company reports, and internal databases. This helps identify key market trends, industry developments, and baseline information.Stage 2: Primary Research
The research team conducts in-depth interviews with industry participants, including manufacturers, suppliers, distributors, importers, wholesalers, installers, and end users. The information collected is carefully verified against secondary research findings.Stage 3: Data Analysis
Data gathered from both primary and secondary research is analyzed, validated, and cross-checked. Additional interviews are conducted whenever necessary to ensure consistency and accuracy.Stage 4: Quantitative Analysis
Market size, production, capacity, forecasts, pricing, and investment analysis are developed using validated data and proprietary research models. This ensures that all market estimates are reliable and unique to VICResearch.Stage 5: Quality Control
Before publication, each report undergoes a comprehensive quality review and editorial process. Continuous analyst training and strict quality control procedures ensure the accuracy, consistency, and reliability of every report.